European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

EC clears first treatment for high-risk smouldering multiple myeloma

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX (daratumumab)

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company,...

European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of...

Dr Burke Discusses Daratumumab in Smoldering Myeloma

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.

European Commission Approves Darzalex Faspro for Treating Smoldering Multiple Myeloma in Adults

The European Commission has granted approval for a new […] The post European Commission Approves Darzalex Faspro for Treating Smoldering Multiple Myeloma in Adults first appeared on GeneOnline News. The post European Commission Approves Darzalex Faspro for Treating Smoldering Multiple Myeloma in Adults appeared first on GeneOnline News.

Janssen’s Darzalex new indication gains EC approval

The EC has approved Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) to treat adults with SMM.